These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3884533)

  • 1. [Molecular biology of paramyxoviruses and its significance for the development of vaccines].
    Scheid A
    Internist (Berl); 1985 Feb; 26(2):98-102. PubMed ID: 3884533
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent developments with live-attenuated recombinant paramyxovirus vaccines.
    Le Bayon JC; Lina B; Rosa-Calatrava M; Boivin G
    Rev Med Virol; 2013 Jan; 23(1):15-34. PubMed ID: 22570186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The status of research to develop new vaccines against infection caused by the respiratory syncytial virus].
    Pervikov IuV; Litvinov SK
    Vopr Virusol; 1988; 33(5):523-9. PubMed ID: 3064426
    [No Abstract]   [Full Text] [Related]  

  • 4. Approaches to immunization against respiratory syncytial virus.
    Wertz GW; Sullender WM
    Biotechnology; 1992; 20():151-76. PubMed ID: 1600380
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent trends in veterinary vaccines.
    Bittle JL
    Prog Clin Biol Res; 1985; 178():621-6. PubMed ID: 4011619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serological studies of pigeon sera for antibodies against a paramyxovirus isolate and Newcastle disease virus following recovery from paramyxovirus infection and after vaccination with a live and dead vaccine].
    Baumbach B; Schneider J
    Dtsch Tierarztl Wochenschr; 1985 Mar; 92(3):90-2. PubMed ID: 3886349
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIV-3 vaccine National Institutes of Health/Aviron.
    Jones T
    Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination against paramyxoviruses.
    McClelland AJ
    Nature; 1980 Apr; 284(5755):404. PubMed ID: 7360279
    [No Abstract]   [Full Text] [Related]  

  • 11. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 12. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection.
    Cole GA; Hogg TL; Coppola MA; Woodland DL
    J Immunol; 1997 May; 158(9):4301-9. PubMed ID: 9126992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.
    Merz DC; Scheid A; Choppin PW
    J Exp Med; 1980 Feb; 151(2):275-88. PubMed ID: 6766174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an intranasal modified live bovine respiratory syncytial virus and temperature-sensitive parainfluenza type 3 virus vaccine in 3-week-old calves experimentally challenged with PI3V.
    Vangeel I; Ioannou F; Riegler L; Salt JS; Harmeyer SS
    Vet J; 2009 Jan; 179(1):101-8. PubMed ID: 17931918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Infection defense antigens against pathogenic viruses to human. Infection defense antigens and genetic code--trend and progress of study on biomolecular analysis. g. Infection defense antigens of paramyxoviruses].
    Kohama T
    Nihon Rinsho; 1987 Oct; 45(10):2263-8. PubMed ID: 3448265
    [No Abstract]   [Full Text] [Related]  

  • 17. The production of monoclonal antibodies against respiratory syncytial virus and its clinical applications.
    Wu B
    Clin Lab Med; 1985 Sep; 5(3):589-613. PubMed ID: 3899483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prospects for the development of viral vaccines].
    Bektimirov TA; Gorbunov MA
    Voen Med Zh; 1995 Jul; (7):45-8. PubMed ID: 7571512
    [No Abstract]   [Full Text] [Related]  

  • 19. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular biology, the new genetics and vaccine development.
    Dougan G; Highfield P
    Med Lab Sci; 1985 Oct; 42(4):393-8. PubMed ID: 3866136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.